July 13, 2018
Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018
Conference Call and Webcast to Follow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 13, 2018--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second
quarter 2018 financial results will be released on Wednesday, July 25,
after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management
will host a conference call to discuss the company’s financial results
for the second quarter 2018 and provide a general business update.
The live webcast of the call can be accessed at the company’s Investors
page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the
conference ID 8988927 to access the call. Telephone replay will be
available approximately two hours after the call through 11:59 p.m.
Eastern Time, July 27, 2018. To access the replay, please call
1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the
conference ID 8988927. The webcast will be archived on www.gilead.com
for one year.
About Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in
Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180713005374/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Investor Relations
